The chimeric antigen receptor T-cell therapy tisagenlecleucel has been approved for a second type of blood cancer; the National Institutes of Health has started recruiting individuals for a database that will include data on more than 1 million people; Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility.
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (sold as Kymriah by Novartis) has been approved for a second type of blood cancer. The new indication will allow tisagenlecleucel to compete directly with the other CAR T-cell therapy approved in cancer, axicabtagene ciloleucel (marketed as Yescarta by Gilead Science), reported Reuters. The new indication is for treatment of large B-cell lymphoma that has worsened despite 2 or more previous lines of therapy. Tisagenlecleucel was first approved in patients up to age 25 with acute lymphoblastic leukemia.
As part of the All of Us program, the National Institutes of Health (NIH) is recruiting individuals for a database that will include data on more than 1 million people. According to The Wall Street Journal, the effort is an attempt to understand the genetics of diseases and healthy aging. The database will be open to researchers and currently only adults are eligible to volunteer their data. NIH will also make efforts to recruit people who are often underrepresented in medical research.
Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility. The administration planned to announce it had rejected the request, but canceled at the last minute, indicating internal disagreements, reported The Hill. Kansas’ request would drop people from the Medicaid program forever after they receive benefits for 3 years.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More